Assessment of the potential public health impact of Herpes Zoster vaccination in Germany

• Egile Nagusiak: Desmond Curran (Egilea), Desirée Van Oorschot (Egilea), Lijoy Varghese (Egilea), Lidia Oostvogels (Egilea), Tomas Mrkvan (Egilea), Romulo Colindres (Egilea), Alfred von Krempelhuber (Egilea), Anastassia Anastassopoulou (Egilea)
• Formatua: Liburua
• Argitaratua: Taylor & Francis Group, 2017-10-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

The aim of this study was to compare the public health impact of introducing 2 Herpes Zoster (HZ) vaccines, Zoster Vaccine Live (ZVL) versus a non-live adjuvanted subunit candidate vaccine (HZ/su), in the German population aged 50+ years split into 3 age cohorts, i.e. 50-59, 60-69 and 70+ years, res...